. Drug-induced osteoporosis/osteomalacia: analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol 2019;75:diciembre. [Ref.ID 103213]

Cummings SR, Lui LY, Eastell R, Allen IE. Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern Med 2019:19 de agosto. [Ref.ID 103179]

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

Vaidya JS, Massarut S, Vaidya HJ, Alexander EC, Richards T, Caris JA, Sirohi B, Tobias JS. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ 2018;360:j5913. [Ref.ID 102449]

Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. BMJ 2016;354:8 de octubre. [Ref.ID 100796]

Donneyong MM, Bykov K, Bosco-Levy P, Dong Y-H, Levin R, Gagne JJ. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ 2016;354:i5014. [Ref.ID 100795]

Anónimo. Ospémifène. Prescrire 2015;35:728-9. [Ref.ID 99842]

Mayer EL, Burstein HJ. Postmenopausal breast cancer: a best endocrine strategy?. Lancet 2015;386:1317-9. [Ref.ID 99617]

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341-52. [Ref.ID 99276]

Chlebowski RT. IBIS-I tamoxifen update: maturity brings questions. Lancet Oncol 2015;16:7-9. [Ref.ID 98773]

Cuzick J, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A, Forbes JF, on behalf of the IBIS-I Investigators. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015;16:67-75. [Ref.ID 98772]

Bischoff-Ferrari HA, Meyer O. Comparative effectiveness of pharmacologic treatments to prevent fractures: is this all we need to know?. Ann Intern Med 2014;161:711-23. [Ref.ID 98329]

Crandall CJ, Newberry SJ, Diamant A, Lim Y-W, Gellad WF, Booth MJ, Motala A, Shekelle PG. Comparative effectiveness of pharmacologic treatments to prevent fractures: and updated systematic review. Ann Intern Med 2014;161:711-23. [Ref.ID 98328]

Anónimo. Drugs for postmenopausal osteoporosis. Med Lett Drugs Ther 2014;56:91-6. [Ref.ID 98234]

Hugo HS. Hormone theray in premenopausal women with early-stage breast cancer. N Engl J Med 2014;371:175-6. [Ref.ID 97810]

Pagani O, Regan MM, Walley BA, Fleming GF, Collecni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Steams V, Bonnefoi HR, Martino S, Geyer Jr CE, Pinotti G, Puglisi F, Crivellari D, Rushtaller T, Winer EP, Rabaglio-Poretti M, Malbach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA, for the TEXT and SOFT Investigators and the International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014;371:107-18. [Ref.ID 97807]

Anónimo. Ranelato de estroncio (Osseor, Protelor): la revisión europea concluye que el balance beneficio-riesgo es desfavorable. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2014:10 de enero. [Ref.ID 96990]

Anónimo. Atteintes de la cornée d'origine médicamenteuse. Prescrire 2013;33:908-13. [Ref.ID 96721]

Anónimo. U.S. FDA approves Pfizer drug for menopause symptoms. Journal Watch 2013:4 de octubre. [Ref.ID 96196]